These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 17440984)

  • 1. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.
    Kittur J; Knudson RA; Lasho TL; Finke CM; Gangat N; Wolanskyj AP; Li CY; Wu W; Ketterling RP; Pardanani A; Tefferi A
    Cancer; 2007 Jun; 109(11):2279-84. PubMed ID: 17440984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.
    Antonioli E; Guglielmelli P; Poli G; Bogani C; Pancrazzi A; Longo G; Ponziani V; Tozzi L; Pieri L; Santini V; Bosi A; Vannucchi AM;
    Haematologica; 2008 Jan; 93(1):41-8. PubMed ID: 18166784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
    Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
    Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
    Sirhan S; Lasho TL; Hanson CA; Mesa RA; Pardanani A; Tefferi A
    Am J Hematol; 2008 May; 83(5):363-5. PubMed ID: 18266209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.
    Hsiao HH; Yang MY; Liu YC; Lee CP; Yang WC; Liu TC; Chang CS; Lin SF
    Exp Hematol; 2007 Nov; 35(11):1704-7. PubMed ID: 17920754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlations of jak2v617f mutation with clinical and laboratory findings in primary thrombocythemia patients].
    Xia J; Xu W; Zhang SJ; Sun XM; Duan LM; Li WD; Qiou HX; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):416-20. PubMed ID: 18426677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
    Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
    Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.
    Yönal İ; Dağlar-Aday A; Akadam-Teker B; Yılmaz C; Nalçacı M; Yavuz AS; Sargın FD
    Turk J Haematol; 2016 Jun; 33(2):94-101. PubMed ID: 25913509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation of JAK2V617F mutation burden with clinical features in patients with polycythemia vera and essential thrombocythemia].
    Liu HX; Tong CR; Cai P; Teng W; Wang H; Zhang Y; Zhu P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):742-5. PubMed ID: 19549399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.
    Tefferi A; Lasho TL; Huang J; Finke C; Mesa RA; Li CY; Wu W; Hanson CA; Pardanani A
    Leukemia; 2008 Apr; 22(4):756-61. PubMed ID: 18216871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status.
    Heller PG; Lev PR; Salim JP; Kornblihtt LI; Goette NP; Chazarreta CD; Glembotsky AC; Vassallu PS; Marta RF; Molinas FC
    Eur J Haematol; 2006 Sep; 77(3):210-6. PubMed ID: 16923108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
    Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
    APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients.
    Pardanani A; Lasho TL; Finke CM; Gangat N; Wolanskyj AP; Hanson CA; Tefferi A
    Leukemia; 2010 Jan; 24(1):110-4. PubMed ID: 19847198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms.
    Alvarez-Larrán A; Angona A; Martínez-Avilés L; Bellosillo B; Besses C
    Leuk Res; 2012 Mar; 36(3):324-6. PubMed ID: 22001278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
    Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
    Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
    Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events.
    Alvarez-Larrán A; Bellosillo B; Pereira A; Kerguelen A; Hernández-Boluda JC; Martínez-Avilés L; Fernández-Rodríguez C; Gómez M; Lombardía L; Angona A; Ancochea A; Senín A; Longarón R; Navarro B; Collado M; Besses C
    Am J Hematol; 2014 May; 89(5):517-23. PubMed ID: 24458835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of JAK2V617F Mutation Burden on Clinial Presentation and Survival in ET Patients].
    Zhao SX; Lu ZX; Yu LQ; Guan X; He HP; Shi KQ; Zhao RB; Yang TH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1497-1501. PubMed ID: 30295274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.